Achieve Life Sciences Stock
Achieve Life Sciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Andrew D. Goldberg
- Employees
- 28
- Market cap
- $657 M
- IPO
- 12/10/1995
Achieve Life Sciences, Inc. operates as a clinical pharmaceutical company in the healthcare/biotechnology sector, focusing primarily on the development and commercialization of Cytisinicline. Headquartered in Vancouver, the company (Ticker: ACHV) conducts its business operations in Canada, the United States, and the…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Achieve Life Sciences stock: price history
1D
-8.5%
1W
-13.9%
1M
-14.0%
6M
+25.1%
YTD
+28.4%
1Y
+107.1%
2Y
+27.6%
5Y
-20.7%
10Y
-99.3%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~16% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Achieve Life Sciences stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Business model with weaknesses or early megatrend headwind.
1 more assignment (Enabler/Second row) Pro-only.
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company primarily focused on the development and subsequent commercialization of the active pharmaceutical ingredient Cytisinicline. The product is designed to support smoking cessation by reducing the intensity of nicotine withdrawal symptoms through interaction with nicotine receptors in the brain. The company plans its commercial activities in Canada, the United States, and the United Kingdom. Through licensing agreements with Sopharma AD and the University of Bristol, the business model relies on the development of proprietary active pharmaceutical ingredients for the treatment of nicotine dependence.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Moderate
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Achieve Life Sciences
Analyst assessment of Achieve Life Sciences
PRICE TARGET LOW
US$12.00
CONSENSUS
US$14.80
MEDIAN
US$13.00
PRICE TARGET HIGH
US$18.00
0
STRONG BUY
6
BUY
0
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 22/06/2026
Achieve Life Sciences stock metrics
P/E
-4.12
P/B
-40.65
EV/EBITDA
-5.53
RETURN ON EQUITY
509.5%
NET MARGIN
0.0%
DEBT/EQUITY
-1.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
72.6%
FLOAT SHARES
74,690,743
AVG. DAILY VOLUME (30D)
1,593,110
Insider transactions (SEC)
Stewart Richard Alistair
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -8.5%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Achieve Life Sciences stock
What does Achieve Life Sciences do?
Achieve Life Sciences, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Andrew D. Goldberg, the company employs around 28 people.
The IPO was on 12/10/1995; the stock trades on NASDAQ under the ticker ACHV.
What do analysts say about Achieve Life Sciences stock?
6 analysts rate the stock, the consensus is Buy (as of 22/06/2026).
The average price target is US$14.80, ranging from US$12.00 to US$18.00, with a median of US$13.00.
This is an external assessment, not a statement by Market Jury.
When does Achieve Life Sciences report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -16% stronger than usual.
Does Achieve Life Sciences pay a dividend?
No, Achieve Life Sciences currently does not pay a dividend.
Which stocks are comparable to Achieve Life Sciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Achieve Life Sciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Achieve Life Sciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.